Profit-Driven Medicine Violates American Patients Young and Old. Though my grandson and I are in two different sections of the country and both facing different cancer scares, we share one thing more prominently than anything else.
We are being violated as human beings in need of medical care by our health providers’ need to protect profits. The money comes first; the patient is but a necessary cog in the healthcare revenue wheel. I know that most of the time when those who advocate for a more sane system under an improved and expanded Medicare for all, for life model target their list of “evil-doers,” we tend to focus on the for-profit health insurance industry.
Clearly, having to fund all the administrative costs, shareholder profits, and CEO salaries for those companies is a driving factor in the ever rising costs of healthcare in America. But the insurance companies aren’t the only ones targeting patients for profits. "Oh, it’s all legal all right. Oh, it’s all legal all right. Bleeding Risk with Blood Thinner Cited - Drug Abuse - • Drug Abuse • Feb 29, 2012 A cluster of bleeding episodes in patients treated with dabigatran (Pradaxa) led a group of New Zealand hematologists to express concern and call for better prescriber education. A two-month review identified 78 bleeding episodes, including a dozen major bleeds, one of which might have contributed to a patient’s death, the hematologists wrote in a letter published in the March 1 issue of the New England Journal of Medicine.
Pradaxa patient's death draws more scrutiny of bleeding risks. The case of a Pradaxa user who died after a minor fall is raising more questions about the drug's safety.
As the FDA investigates a series of deaths in Pradaxa patients, a new report in the Journal of Neurosurgery details an 83-year-old man's death from a small brain hemorrhage that quickly grew, and didn't respond to efforts to stop it. "In the event of traumatic hemorrhage in patients receiving dabigatran ... there are currently no effective reversal agents," the report said (as quoted by Reuters). Because Boehringer Ingelheim's Pradaxa is cleared by the kidneys, dialysis has been suggested to neutralize its anticoagulant effects. This particular patient wasn't put on dialysis because "it was too late to implement effectively" as his condition rapidly deteriorated, the article states.
Sign up for our FREE newsletter for more news like this sent to your inbox! New anticoagulant drug and head injury: Do not mix. Factors raising risk of stroke may also raise the risk of memory loss and… (Ricardo DeAratanha / Los…) Dabigatran (marketed as Pradaxa) is a new drug used by a growing number of Americans with atrial fibrillation.
It's both easier to take and more effective at reducing the risk of stroke than warfarin, a drug that's been in use since the 1950s. But a case report published this week underscores a danger with the new medication: If a patient taking it is bleeding into the brain or elsewhere, there is currently no fast, effective way to reverse the blood-thinning agent's effects. For one 83-year-old man who was taken to the University of Utah Hospital's emergency department after falling and hitting his head, the result was death. Pradaxa Under Fire by British Regulators. Boehringer Ingelheim, the maker of Pradaxa have been cited by the Prescripton Medicines Code of Practice Authority (PMCPA), a British regulatory agency, for the information on the Pradaxa’s website.
The British regulatory agency has cited Boehringer Ingelheim’s Pradaxa website for violating industry codes of conduct. It also charged the company over issues related to a press release. The allegations were brought by a general practitioner, who began investigating after seeing a press release from the company that described the blood thinner warfarin as “rat poison” and referred to Pradaxa as a “wonder drug.” The article also failed to properly warn about the bleeding side effects of Pradaxa. An investigation into the Pradaxa website led to the PMCPA’s ruling that the site violated the Association of the British Pharmaceutical Industry’s (ABPI) code of practice. Fatal G.I. Hemorrhage Prompts Pradaxa Wrongful Death Lawsuit. Home > Legal News > Fatal G.I.
Hemorrhage Prompts Pradaxa Wrongful Death Lawsuit After her death from a severe gastrointestinal bleed, the family of a Tennessee woman has filed a wrongful death lawsuit against Pradaxa maker Boehringer Ingelheim. The suit is based on allegations that the drug maker was negligent in its duty to warn doctors and patients of the serious risks linked to this new blood thinner. The late Nancy Brummett’s daughter, Bertha Bivens, filed the complaint in the U.S. District Court for the Eastern District of Tennessee.
The Debate Over Pradaxa (Dabigatran) Safety - Follow the Money. Boehringer Ingelheim, a German pharmaceutical company beat all competitors to the market with its new wonder drug Pradaxa.
The new drug was touted as equal or superior to Coumadin (Warfarin) for preventing strokes in patients suffering from Atrial Fibrillation. In addition, because of its properties, Pradaxa provided the added convenience of not requiring regular blood level monitoring. The study upon which it based those claims was funded by…you guessed it…Boehringer Ingelheim.
Soon after completion of the study, a hoard of doctors began publishing their findings in medical journals such as the New England Journal of Medicine. The main authors of the article have one thing in common. Soon thereafter, doctors began conducting studies and publishing letters to the editor criticizing Pradaxa (Dabigatran) for causing deaths from what appeared to be excessive, uncontrolled bleeding. The doctors critical of Pradaxa also had one thing in common. That was not the final word. The Dangers of Pradaxa (Dabigatran): Part 1 of 3: Side Effects and Complications. Mar 28 Wednesday, March 28, 2012.
Pradaxa Lawsuit. Call 888-377-8900 for a free consultation regarding a Pradaxa lawsuit.
Attorney Brendan Flaherty is lead attorney for our Pradaxa lawsuit cases. An investigation of Pradaxa (dabigatran etexilate) has found that this medication can cause irreversible bleeding. In some cases, people who took Pradaxa for a brief period of time were at increased risk for life-threatening bleeding. Are you someone who suffered from severe bleeding after taking Pradaxa? If so, Brendan Flaherty and his team of attorneys can help you win your case. Injury Lawyer Network Announces New Helpline for Pradaxa Injury Victims. PRLog (Press Release) - Apr. 3, 2012 - Injury Lawyer network has launched a Pradaxa Helpline for victims of the anti-coagulant Pradaxa.
Pradaxa has shown to have side effects and complications which can lead to death.The FDA issued a Safety Announcement for Pradaxa which points to heart problems with Pradaxa. The U.S. Food and Drug Administration (FDA) is evaluating post-marketing reports of serious bleeding events in patients taking Pradaxa (dabigatran etexilate mesylate). Pradaxa Overdose and Hemorrhages Report. The blood thinner Pradaxa, (subject of 6 wrongful death US lawsuits), according to a new FDA report, may have been responsible for another 117 deaths during the second quarter of 2011.
The Institute for Safe Medication Practices (ISMP) published their quarterly report (PDF) earlier this week on adverse event reports between April and June 2011. Adverse Bleeding Events Persist Among Pradaxa Patients, Resulting in Serious Injury and Death. 09 April 2012 Faith Anderson According to a new report submitted to the FDA by the Institute for Safe Medication Practices (ISMP), the controversial blood thinner Pradaxa may have been responsible for another 117 deaths during the second quarter of 2011.
The ISMP released their quarterly report earlier this week on adverse event reports submitted by patients and healthcare providers throughout the United States between April and June 2011. In light of the frequency and severity of Pradaxa adverse events, the blood thinner holds the dubious title of being associated with more reported side effects than any other regularly monitored drug, even though the medication had been on the market for less than a year at the time. New Blood Thinner Pradaxa Associated With Bleeding Side Effects Pradaxa was developed by drug firm Boehringer Ingelheim and garnered FDA approval in October 2010 to prevent blood clots and stroke in patients with atrial fibrillation.
California Pradaxa Attorneys. 1inShare The blood-thinning drug Pradaxa (dabigatran) has been linked to a number of serious complications, including an increased risk of serious and in some cases, fatal, bleeding events. Boehringer Ingelheim, the company that manufactures Pradaxa, acknowledged in November 2011 that the drug was responsible for approximatley 260 deaths worldwide. A new report issued by the Food and Drug Administration (FDA) last week suggests that additional patient deaths may be attributed to Pradaxa in the U.S. The Institute for Safe Medication Practices released a new QuarterWatch report on April 5th.
QuarterWatch tracks adverse event reports submitted to the FDA for each quarter of the year. New Blood Thinner Similar to Pradaxa: Risk of Internal Bleeding. Home > Legal News > New Blood Thinner Similar to Pradaxa: Risk of Internal Bleeding Merck & Co. has introduced a new blood thinner which is in the same class as Pradaxa and Xarelto, which also poses an increased risk of potentially fatal internal bleeding. This new anticoagulant, Vorapaxar, appears to reduce the risk of a fatal heart attack or stroke by roughly 20% in patients who have already suffered a heart attack. Pradaxa Internal Bleeding Concerns Mount after Patient Dies. Home > Legal News > Pradaxa Internal Bleeding Concerns Mount after Patient Dies After an elderly man died from a brain hemorrhage, the Journal of Neurosurgery has suggested that Pradaxa internal bleeding is largely irreversible.
Pradaxa (dabigatran) is the first in a new class of blood thinners known as direct thrombin inhibitors. These anticoagulants are prescribed to patients with atrial fibrillation and are at risk for blood clots and strokes. Pradaxa Bleeding Deaths Reported in 117 More Patients, ISMP Finds. Pradaxa Internal Bleeding Class Action Lawsuit Investigation. New Sub-Analysis Evaluates Outcomes Associated with Lower Intracranial Hemorrhage Rates for Pradaxa® (dabigatran etexilate mesylate) Versus Warfarin in the RE-LY® Trial. Pradaxa Causing Serious Bleeding: FDA to Conduct Safety Review. The U.S. Food and Drug Administration (FDA) is reviewing reports that hundreds of patients taking Pradaxa (dabigatran etexilate mesylate) have suffered from serious bleeding events. Boehringer Ingelheim study shows safety benefits of Pradaxa.
Pradaxa, Minor Injuries & Internal Bleeding / Drug Injury Lawyers. Pradaxa associated with significantly lower rates of fatal and traumatic intracranial haemorrhage compared with Warfarin. A new analysis of the 18,113 patient, RE-LY trial highlights significantly lower rates of both fatal and traumatic intracranial haemorrhage (ICH) in patients treated with dabigatran etexilate (Pradaxa) 110mg and 150mg bid compared to those treated with well-controlled warfarin.
As part of the primary safety endpoint, the analysis evaluated 154 intracranial haemorrhages that occurred in 153 patients during the trial, including bleeding sites, rates, risk factors, associated trauma, and outcomes. Search and Get There Faster.